Mustang Bio Inc. (MBIO)
| Bid | 1.06 |
| Market Cap | 3.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.75M |
| EPS (ttm) | -8.6 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | -0.01 |
| Analyst | Buy |
| Ask | 1.12 |
| Volume | 166,220 |
| Avg. Volume (20D) | 432,595 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.06 - 1.12 |
| 52-Week Range | 1.01 - 65.00 |
| Beta | 2.14 |
About MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develo...
Analyst Forecast
According to 1 analyst ratings, the average rating for MBIO stock is "Buy." The 12-month stock price forecast is $100, which is an increase of 9032.42% from the latest price.
Stock Forecasts
11 months ago · https://www.defenseworld.net
HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 earnings estimates for Mustang Bio in a research note issued to investors on Thursday, May 1...